ARTICLE | Clinical News

BPSC1001: Phase I started

October 27, 2014 7:00 AM UTC

NIH's National Institute of Allergy and Infectious Diseases (NIAID) began a dose-escalation Phase I trial to evaluate 3 dose levels of NewLink's VSV-EBOV in about 39 healthy adults. Subjects will receive 2 intramuscular injections of VSV-EBOV given 28 days apart and will be re-evaluated 11 times over 1 year. Initial safety and immune response data are expected by year end. ...